Reichman, D.E., Zakarin, L., Chao, K., Meyer, L., Davis, O.K., Rosenwaks, Z.: Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil. Steril., 102: 99-102,2014.
Bosch, E., Valencia, I., Escudero, E., Crespo, J., Simon, C., Remohi, J., Pellicer, A.: Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil. Steril., 80: 1444-1449,2003.
Richter, T.A., Robinson, J.E., Evans, N.P.: Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a Stimulatory estradiol signal in the ewe. Biol. Reprod., 67: 119-125,2002.
Wikstrom, A., Green, B., Johansson, E.D.: The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses. Acta Obstet. Gynecol. Scand., 63: 163-168,1984.
Kuang, Y., Chen, Q., Fu, Y., Wang, Y., Hong, Q., Lyu, Q., Ai, A., Shoham, Z.: Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril., 104: 62-70,2015.